Daniel F. Kiernan, MD, FACS, - Cirriculum Vitae 941-792-2020 or toll Free 1-866-865-2020

Fellowship- Vitreo-Retinal University of Illinois Eye and Ear Infirmary, Chicago, Illinois

Residency - University of Chicago Hospital, Pritzker School of , Chicago, Illinois

Internship Advocate Illinois Masonic Medical Center Chicago, Illinois

Doctorate of Medicine Chicago /Rosalind Franklin University, Chicago, Illinois

Bachelor of Arts in Biology University of Chicago Chicago, Illinois

PROFESSIONAL ASSOCIATIONS AND APPOINTMENTS American Academy of Ophthalmology (AAO) American Society of Retinal Specialists (ASRS) The Association for Research in Vision and Ophthalmology (ARVO) Pan-American Association of Ophthalmology (PAAO) International Society of Refractive Surgeons (ISRS) American College of Surgeons American Medical Association (AMA) Society Vit-Buckle Society Nassau Surgical Society Long Island Ophthalmology Society New York State Ophthalmological Society Medical Society of the State of New York Nassau County Ophthalmology Society Suffolk County Medical Society National Eagle Scout Association (NESA) Daniel F. Kiernan - Curriculum Vitae, page 2 HONORS AND AWARDS: Age-Related Center of Excellence - The Macular Degeneration Association- 2019 New York Times Best Doctors NYC Metro Region, 2019 Super Doctors Rising Stars, New York Metro Area, 2019 Fellow, American College of Surgeons (FACS), October 2018 Science Direct, 11th Most Requested Article, Am J Ophthalmology: Spectral Domain OCT: A Comparison of Modern High Resolution Retinal Imaging Systems, 2011 11th Annual Retina Fellows Forum Bowling Tournament Top Team Score, 2011 5th Annual Retina Fellows Reception and Retinal Jeopardy Tournament Champion, 2010 AAO Meeting Poster Star Award (Inherited Retinal Disease): Thirty-Year Follow-up of an African-American Family with North Carolina Macular Dystrophy, 2010 Science Direct, Most Requested Article, Am J Ophthalmology: Spectral Domain OCT: A Comparison of Mod- ern High Resolution Retinal Imaging Systems, 2010 9th Raymond R. Margherio Award - Retina Society, 2010 Jedd Retina Research Travel Grant Recipient (University of Illinois) - ASRS Meeting, 2010 American Retina Foundation Travel Grant Recipient - AOS Meeting, 2010 Alfred E. Potts Award for Resident Research - University of Chicago, 2009 Beem-Fisher Award for Resident Research, 2nd Place - Chicago Ophthalmological Society, 2009 Paul Kayser International Scholarship Award - Pan-American Association of Ophthalmology, 2009 Alfred E. Potts Award for Resident Research - University of Chicago, 2008 America at Home photography selectee- pp. 98-99: Cheap Seats in Wrigleyville, 2008 www.myamericaathome.com/customcover/inside.php click page right 11 times Career Eye Institute Program Competition Winner, 2008 Archives of Ophthalmology Online Quiz Winner, April 2008 National Eye Institute Travel Grant Recipient – ARVO Meeting, Retina subsection, 2007 National Eagle Scout Award; Troop 60 Merit Badge Record (53), 1996

SCIENTIFIC JOURNAL ARTICLE PEER REVIEWER BMJ Open Ophthalmology, 2019-20 EyeWiki Editor, Retina Subsection. American Academy of Ophthalmology. 2017-19 Eye (London – Nature), 2013-16 JAMA (formerly Achieves of) Ophthalmology, 2009-18 Retina, 2011-18 International Journal of Inflammation, 2012-13 BMC Ophthalmology, 2012 Journal of the American Medical Association, 2012-4 Journal of Ocular Pharmacology and Therapeutics, 2010-12 Retinal Cases and Brief Reports, 2010-18 Ophthalmology, 2008-18 Investigative Ophthalmology and Visual Science, 2010-18 Retinal Physician, 2010-16

RESEARCH - CLINICAL TRIALS

Principal Investigator: A Phase 2A/2B Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects with Neovascular Age-related Macular Degeneration (ALTISSIMO) – Phase II Graybug Vision, Inc. Protocol# GBV-102-002 November 2019 CRO / ORA Daniel F. Kiernan - Curriculum Vitae, page 3

Sub-Investigator: Phase III Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2 Neurotech Pharmaceuticals Inc. Protocol No. NTMT-03-A March 2019

Sub-Investigator: A Natural History Observation and Registry Study of Macular Telangiectasia Type 2 – The Mactel Study Study Sponsor: The Lowy Medical Research Institute Protocol No: NHOR March 2019 Coordinating Center: The Emmes Corporation Phase: Observation / Registry

Sub-Investigator: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macula Degeneration – Phase III – The TENAYA Study Genentech-Hoffmann-LaRoche Ltd. Protocol No. GR40306 February 2019

Sub-Investigator: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with in Patients with Neovascular Age-Related Macular Degeneration – Phase III – The ARCHWAY Study Genentech Hoffmann-LaRoche Ltd. Protocol No. GR40548 January 2019

Sub-Investigator: Multicenter, Randomized, Double-Masked, Active Comparator Controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic (DME) - Phase III Hoffmann-La Roche , Ltd. Protocol# GR40398 (RHINE Study) November 2018

Sub-Investigator: A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Combi- nation with an Intravitreal Anti-VEGF Agent in Subjects with Retinal Vein Occlusion - Phase: III - IND # 115683 Clearside Biomedical, Inc. Protocol # CLS1003-302 2018

Principal Investigator: Multicenter, Open-Label, Single-Arm Study to Evaluate Abicipar for Safety and Treatment Effect in Patients with Neovascular Age-Related Macular Degeneration (AMD) – Phase II Allergan Protocol # 1771-201-008 The MAPLE Study May 2018

Sub-Investigator: A Randomized, Sham-Controlled, Double-Masked, Phase 2a Study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects with Center-Involving Diabetic Macular Edema (ciDME) who have had Prior Anti-Vascular Endothelial Growth Factor (VEGF) Treatment – Phase IIa KalVista Pharmaceuticals, Ltd. Protocol# KVD001-201 January 2018 CRO / ORA

Principal Investigator: A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formu- lation of Sunitinib Malate (GB-102) in Subjects with Neovascular Age-related Macular Degeneration – Phase I Graybug Vision, Inc. Protocol# GBV-102-001 January 2018 CRO / ORA Daniel F. Kiernan - Curriculum Vitae, page 4 Sub-Investigator: A Dose-Ranging Study of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibi- zumab Alone, in Participants with Neovascular Age-Related Macular Degeneration (wet AMD) – Phase IIb Opthea Ltd. Protocol# OPT-302-1002 November 2017

Sub-Investigator: The Role of CEP and iNKT T-cells in Patients with Advanced Age-Related Macular Degeneration (AMD) – Phase: Pilot Investigator Sponsored Protocol# GLS-42017 Grantor: Apellis Pharmaceuticals, INC April 2017

Sub-Investigator: STAIRWAY: Simultaneous Blockage of Angiopoietin-2 and VEGF-A with the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macula Degeneration – Phase II Hoffmann-La Roche, Ltd. Protocol# CR39521 February 2017

Sub-Investigator: A Multi-Center, Open Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampali- zumab in Patients with Geographic Secondary to Age-Related Macular Degeneration who have Completed a Roche-Sponsored Study – Phase IIIb Hoffmann-La Roche , Ltd. Protocol# GX30191 - Omaspect Study October 2016

Principal Investigator: A Phase 4 Safety Study of IOP Signals in Patients Treated with Iluvien® (Fluocinolone Acetonide Intravitreal Implant) 0.19 MG. Phase 4 IOP Signals Associated with ILUVIEN (The Paladin Study) – Phase: IV Alimera Sciences, Inc. Protocol # M-01-15-004 June 2016

Sub-Investigator: OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration – Mako Study - Phase III Ohr Pharmaceutical, Inc. Protocol # OHR-1601 May 2016

Sub-Investigator: A Multi-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of RO6867461 Adminis- tered Intravitreally in Patients with Diabetic Macular Edema – Phase II – The Boulevard Study Genentech / La Roche Ltd. Protocol # BP30099 April 2016

Sub-Investigator: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double- Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Effi- cacy of RO6867461 Administered Intravitreally in Patients with Choroidal Secondary to Age-Related Macular Degeneration – Phase II – AVENUE Study Genentech (Hoffman-La Roche) Protocol# BP29647 January 2016

Principal Investigator: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular De- generation – The CEDAR Study – Phase III Allergan, Inc. Protocol#150998-005 July 2015 Daniel F. Kiernan - Curriculum Vitae, page 5 Sub-Investigator: A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema-VIDI Study Astella Pharma Europe B.V. Protocol # 832-CL-3001 March 2015

Sub-Investigator: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess Efficacy and Safety of Lampalizumab Administered Intravitrally to Patients with Geographic Atrophy Secondary to Age-Related Macula Degeneration Genentech / Hoffmann-LaRoche Protocol # GX29176 CHROMA Spetember 2014

Sub-Investigator: Evaluation of Abicipar Pegol (AGN-150998) in Patients with Decreased Vision Due to Diabetic Macular Edema – Phase II Allergan Protocol # 150998-004 (PALM) September 2014

Sub-Investigator: Ocriplasmin Research to Better Inform Treatment (ORBIT) – Phase: IV ThromboGenics, Inc. Protocol# TG- MV-018

Sub-Investigator: A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy As- sociated with Dry Age-Related Macular Degeneration Acucela Protocol # 4429-202 February 2013 Target:8, Screened: 12, Actual: 4

Sub-Investigator: Treatment with Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T. Study Investigator Sponsor Trial Protocol # ACT2013 November 2012 Target: 20, Screened: 23, Actual: 20

Sub-Investigator: Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Multi-Dose Study to Investigate the Effica- cy, Safety, Pharmacokinetics and Pharmacodynamics of RN6G (PF-043382923) in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration - Phase II Pfizer Protocol # B1181003 September 2012

Sub-Investigator: A Multicenter, Randomized, Single-Masked, Sham-Controlled, Proof-of-Concept Study of Intravitreal AL- 78898A in Patients With Bilateral Geographic Atrophy (GA) Associated With Age-Related Macular Degenera- tion (AMD) – Phase II Alcon Research, Ltd. Protocol #C-12-020 August 2012 Closed by Sponsor Nov 2012

Sub-Investigator: Compare the Efficacy of 700µg DEX PS DDS with Ranibizumab 0.5 mg Intravitreal Injections in Patients with Diabetic Macular Edema (DME) –Phase IIIb Allergan, Inc. Protocol # 206207-024 August 2012 Target: 5, Screened: 1; Randomized: 1

Sub-Investigator: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of FCFD4514S in Patients with Geographic Atrophy Genentech, Inc. Protocol# GX28198 “OLE” June 2012 Actual: Rollover subjects from MAHALO Actual: 2 Daniel F. Kiernan - Curriculum Vitae, page 6 Sub-Investigator: A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema – Phase III Regeneron Pharma- ceuticals, Inc. Protocol # VGFT-OD-1009 (VISTA) August 2011 Target: 4, Screened: 4, Randomized: 3, Actual: 3, 1 screen failed

Sub-Investigator: Safety, Tolerability and Efficacy Study of ESBA1008 Versus Lucentis® in the Treatment of Exudative Age-Relat- ed Macular Degeneration – Phase I Alcon Research, Ltd.Protocol # C-10-083 (SEE) June 2011 Target: 5 , Screened: 4, Randomized: 3

Sub-Investigator: A 6-month, Phase II, Double-Masked, Multicenter, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and 2%) Twice Daily for the Treatment of Center-Involving Clinically Significant Macular Edema Associated with Dia- betic Retinopathy-Phase II FOVEA Pharmaceutical SA Protocol# FOV2304/CLIN/201/P June 2011 Target: 4, Screened: 13, Randomized: 4

Sub-Investigator: A Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514s Intravitreal Injections Administered Monthly or Every Other Month To Patients With Geographic Atrophy Phase Ib/II Genentech, Inc. Protocol CFD4870g (MAHALO) April 2011 Target: 10, Screened: 11, Randomized: 3

SERVICE WORK

Suffolk County Department of Stepping Up Program for Elderly Education; Aug-Nov, 2011. Lead Presenter at five assisted living facilities in Suffolk County, Vision, Age and Your Ocular Health

2011-2015 Contributor to Team OCLI: Making Strides Against Breast Cancer’ - annual fund-raiser for breast cancer research through donations to the American Cancer Society

Macular Degeneration Association Public Awareness Program Co-Chairman, Macular Degeneration: Predict, Protect and Preserve. Sep 8, 2012. Hofstra University, Hempstead, NY.

Macular Degeneration Association Public Awareness Program Co-Chairman, Macular Degeneration: Save Your Vision! Sep 7, 2013. Hyatt Regency Long Island, Hauppauge, NY.

2011-Present Participant in Rotacare, Long Island, NY - a charitable program dedicated to facilitating free health care for those who have the most need and the least access to medical care http://www.rotacareny. org/ Daniel F. Kiernan - Curriculum Vitae, page 7 EDUCATIONAL PRESENTATIONS

Nassau County Optometric Society Meeting; Aug 18, 2011. Invited speaker, Mystery Retina Cases

Ophthalmic Consultants of Long Island (OCLI) 13th Continuing Education Day for ; Nov 6, 2011. Presenter, Mystery Cases of the Retina, Vitreous and Macula

Suffolk County Optometric Society Meeting; Nov 15, 2011. Invited speaker, Mystery Retina Cases

Ophthalmic Consultants of Long Island 14th Continuing Education Day for Optometry; Mar 18, 2012. Pre- senter, Update on Optical Coherence Tomography Technology

OCLI Educational, Scientific, and Clinical exchange Dinner with Allergan: Scientific and Clinical Applications of Ozurdex. March 5, 2012.

OCLI Educational, Scientific, and Clinical exchange Dinner with Allergan: Clinical Applications of Ozurdex for Retinal Vein Occlusion and Posterior Uveitis. June 19, 2012.

OCLI Educational, Scientific, and Clinical exchange Dinner with Allergan: Treatment of Posterior Uveitis As- sociated with Irvine-Gass Syndrome and Cystoid Macular Edema. Oct 11, 2012.

American College of Surgeons and Nassau Surgical Society Clinic Day; Dec 5, 2012. Presenter, Ocriplasmin for the Management of Vitreomacular Traction.

Ophthalmic Consultants of Long Island 16th Continuing Education Day for Optometry; Apr 7, 2013. Present- er, Diabetic Retinopathy, CSR and Macular Nutrition, and The Vitreous: Everything You Wanted to Know (… but Were Afraid to Ask!)

Suffolk County Optometric Society Meeting; May 20, 2013. Guest Speaker, Age-Related Macular Degenera- tion: 2013 Update.

OCLI Educational, Scientific, and Clinical exchange Dinner with Allergan: Long Term Treatment of Ozurdex for RVO: Review of the SHASTA Study; Expanded Applications for Ozurdex including DME concurrent with RVO. June 12, 2013.

OCLI Educational, Scientific, and Clinical exchange Dinner with Allergan: Non-Infectious Posterior Uveitis, Retina Vein Occlusion Associated with Macular edema, and now Diabetic Macular Edema: The Rise of Ozur- dex for Posterior Segment . Oct 28, 2014.

OCLI Educational, Scientific, and Clinical exchange Dinner with Allergan: Evolving Treatment Strategies for Reducing the Burden of Posterior Segment Diseases: An Interactive Dinner Discussion. Feb 25, 2015.

American College of Surgeons and Nassau Surgical Society Clinic Day; Dec 2, 2015. Presenter, Emerging Treatments for Diabetic Macular Edema.

OCLI Educational, Scientific, and Clinical exchange Dinner with Allergan: Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-Related Macular Degeneration - Review of Phase II outcomes and discussion of upcoming CEDAR trial among retinal specialists and clinical trial coordinators. Jan 13, 2016. Daniel F. Kiernan - Curriculum Vitae, page 8

OCLI Educational, Scientific, and Clinical exchange Dinner with Allergan: Safety and Efficacy of Abicipar Pegol n Patients with Neovascular Age-Related Macular Degeneration – The CEDAR Study – Review of Phase II outcomes and discussion of Phase III Trials among Long Island retina specialists. May 18, 2016.

OCLI Educational, Scientific, and Clinical exchange Dinner with Allergan: Contralateral eye-to-eye compari- son of intravitreal ranibizumab and sustained release dexamethasone in recalcitrant DME. Cases and retina specialist group discussion. Sep 21, 2016.

Ophthalmic Consultants of Long Island 25th Continuing Education Day for Optometry. Presenter, 2017 Up- date on Retinal Treatments. Sep 17, 2017.

Invited Speaker, University of Tennessee Department of Ophthalmology Hamilton Eye Clinic Lecture: Review and Retina Update of Sickle Cell Disease. October 13, 2017.

Invited Speaker, Nassau University New York Medical Center Department of Ophthalmology Grand Rounds: Review and Retina Update of Sickle Cell Disease. October 19, 2017.

American College of Surgeons and Nassau Surgical Society Clinic Day; Dec 6, 2017. Presenter, Genetic Thera- pies for Retinal Disease.

Kiernan DF. Evaluating the Economic and Societal Challenges of Diabetic Retinopathy and Diabetic Macular Edema. Times Continuing Education Specialty Pharmacy Summit 2019. Presented May 2, 2019.

Stolpe S, Mali JM, Dunn JD, Kiernan DF. Advances in the Treatment Landscapes of Wet Age-Related Macular Degeneration. Pharmacy Times Continuing Education, February 28, 2020.

BIBLIOGRAPHY:

Peer Reviewed Articles:

1. Kiernan DF, Hariprasad SM, Chin E, Kiernan CL, Rago JA, Mieler WF. Prospective Comparison of Cirrus versus Stratus Optical Coherence Tomography for Quantifying Retinal Thickness. Am J Ophthalmology 2009;147(2):267-275.e2.

2. Kiernan DF, Lin TK, Sheth V, Jager R. Pharmacotherapy of Retinal Diseases with Ranibizumab. Clinical Medicine: Therapeutics 2009;1:175-182.

3. Kiernan DF, Chin EK, Sclafani LA, Saidel MA. Multi-Drug Resistant Alcaligenes xylosoxidans Keratitis in a Sanitation Worker. Eye and Contact Lens 2009;35(4):212-4.

4. Kiernan DF, Mieler WF. The Use of Intraocular Corticosteroids. Expert Opin. Pharmacother 2009;10(15):2511-25.

5. Kiernan DF, Hariprasad SM, Mieler WF. Spectral Domain OCT: A Comparison of Modern High Resolution Retinal Imaging Systems. Am J Ophthalmology 2010;149(1): 18-31.

6. Kiernan DF, Lin RC, Grassi MA. Sarcoidosis-associated Unilateral Retinal Arteritis. Ocul Immunol Inflamm 2010;18(1):10-2. Daniel F. Kiernan - Curriculum Vitae, page 9

7. Kiernan DF, Hariprasad SM, Mieler WF. Variety, Variability and Veracity: Macular Thickness and Reproduc- ibility among Optical Coherence Tomography Systems. Am J Ophthalmology 2010;150(2):138-40.

8. Hong QV, Kiernan DF, Chau FY, Shapiro M, Blair MP. of recurrent retinopathy of prematurity after initial intravitreous treatment. Arch Ophthalmol 2010;128(8):1080-1.

9. Kiernan DF, Ksiazek SM, Jampol LM, Grassi MA. Photoreceptor Attenuation in Acute Zonal Occult Outer Retinopathy. Retina Cases Brief Rep 2010;4(4):339-345.

10. Kiernan DF, Blair MP, Shapiro MJ. In Utero Diagnosis of Norrie Disease and Early Laser Preserves Visual Acuity. Arch Ophthalmol 2010;128(10):1382.

11. Chow CC, Kiernan DF, Chau FY, Blair MP, Ticho BH, Galasso JM, Shapiro MJ. Laser Photocoagulaion at Birth Prevents Blindness in Norrie Disease Diagnosed Using Amniocentesis. Ophthalmology 2010;117(12):2402-6.

12. Kiernan DF, Hariprasad SM, Rusu IM, Mehta SV, Mieler WF, Jager RD. Epidemiology of the Association between Anticoagulants and Intraocular Hemorrhage in Patients with Neovascular Age-Related Macular Degeneration. Retina 2010;30(10):1573-8. Recipient of 2nd Place Beem-Fisher Award for Resident Research, Chicago Ophthalmological Society.

13. Kiernan DF, Blair MP, Shapiro MJ. Early Treatment of Peripheral Nonperfusion after Nonaccidental Trauma. Ophthalmology 2010;117(12):2443.e1-2.

14. Shapiro MJ, Chow CC, Karth PA, Kiernan DF, Blair MP. Effects of Green Diode Laser in the Treatment of Advanced Coats Disease. Am J Ophthalmology 2011;151(4):725-731.e2.

15. Kiernan DF, Al-Heeti O, Keenan J, Lichtenstein SJ, Blair MP, Shapiro MJ. Peripheral Retinal Nonperfusion in Septo-Optic Dysplasia (De Morsier Syndrome). Arch Ophthalmol 2011;129(5):671-3.

16. Kiernan DF, Shah RJ, Hariprasad SM, Grassi MA, Small KW, Kiernan JP, Mieler WF. Thirty-Year Follow-up of an African-American Family with North Carolina Macular Dystrophy. Ophthalmology 2011;118(7):1435-43.

17. Hu J, Chow CC, Kiernan DF, Garcia-Valenzuela E, Mafee, MF, Blair MP, Shapiro MJ. Peripheral Retinal Nonperfusion Associated with Optic Nerve Hypoplasia and Lissencephaly. Arch Ophth 2012;130(3)398-400.

18. Williams BK, Kiernan DF, Chau FY, Blair MP, Mieler WF. Vitreomacular Adhesion Associated with Foveal-Sparing Preretinal Hemorrhage. Retina Cases Brief Rep 2012;6(3)249-252.

19. Kiernan DF, Zelkha R, Hariprasad SM, Lim JI, Blair MP, Mieler WF. En Face Spectral Domain Optical Coherence Tomography Outer Retinal Analysis and Relation to Visual Acuity. Retina 2012;32(6)1077-1086.

20. Kiernan DF, Mieler WF. Intraocular Corticosteroids for Posterior Segment Disease: 2012 Update. Expert Opin. Pharmacother 2012;13(12):1679-94. Daniel F. Kiernan - Curriculum Vitae, page 10

21. Shapiro MJ, Chow CC, Blair MP, Kiernan DF, Kaufman LM. Peripheral Nonperfusion and Tractional Retinal Detachment Associated With Congenital Optic Nerve Anomalies. Ophthalmology. 2013; 120(3):607-15.

22. Kiernan DF, Hariprasad SM. Controversies in the management of Irvine-Gass syndrome. Ophthalmic Surg Lasers Imaging Retina. 2013 Nov 1;44(6):522-7.

23. Kiernan CL, Kiernan DF. Advancing OCT Algorithmic Standardization. Investigative Ophthalmology and Visual Science. 2014 Apr 11;55(4):2336.

24. Shukla SY, Afshar AR, Kiernan DF, Hariprasad SM. Outcomes of chronic macular hole surgical repair. Indian J Ophthalmol. 2014 Jul;62(7):795-8.

25. Sigler EJ, Randolph JC, Kiernan DF. Longitudinal analysis of the structural pattern of pseudophakic cystoid macular edema using multimodal imaging. Graefes Arch Clin Exp Ophthalmol. 2016 Jan;254(1):43-51.

26. Kiernan D., Gene in the treatment of retinal disease. AudioDigest Ophthalmology. 56:07(Apr7), 2018.

27. Mansour S, Kiernan DF, Roth D, Eichenbaum, D, Holekamp N, Kaba S, Werts E. PALADIN Investigators. The PALADIN study: 24-month interim results of an observational safety study in patients treated with ILUVIEN.. British J Ophthal. 2019 Nov. In Press.

28. Kiernan DF. Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery. BMJ Open Ophthalmology 2020;5:e000491.

29. Hu HJ, Kiernan DF, Eichenbaum D, Sheth VS, Wykoff CC. Home Monitoring of Intermediate Dry Age- Related Macular Degeneration: Real World Utility of the ForeseeHome Device for Detection of Neovascular Conversion. Ophthalmology Retina 2020. Accepted for publication Aug 12, 2020.

Non-Peer Reviewed Articles:

1. Kiernan DF, Marsh CA, Kiernan JP. Your Guide to Error Free Cataract Surgery. Outpatient Surgery 2003 Apr:74-6.

2. Kiernan DF, Lin TK, Jager R. On the Horizon: Genetic Therapy for Age-Related Macular Degeneration. Retinal Physician 2008 Sep:50-6.

3. Kiernan DF, Hariprasad SM, Mieler WF. Modern High Resolution OCT systems. Ophthalmology International 2009;3(4):23-27.

4. Sheth VS, Lin TK, Kiernan DF, Jager RD. Ciliary Neurotrophic Factor in the Treatment of Advanced Nonexudative Age-Related Macular Degeneration. AMD Update 2009 Jul;33.

5. Kiernan DF, Hariprasad SM. Spectral-Domain Optical Coherence Tomography: Comparing Commercially Available Systems for Managing Patients with Age-Related Macular Degeneration. AMD Update 2010 Feb;38. Daniel F. Kiernan - Curriculum Vitae, page 11

6. Kiernan DF, Hariprasad SM. Normative Databases in SDOCT: A Status Report. Retinal Physician 2010 Apr:16-29.

7. Kiernan DF, Lim JI. Topical Drug Delivery for Posterior Segment Disease. Retina Today 2010 June:48-51.

8. Kiernan DF. Antiplatelet, anticoagulant therapy may pose risk for patients with neovascular AMD. Ocular Surgery News U.S. Edition, February 10, 2011.

9. Kiernan DF, Hariprasad SM. Controversies in Managing Macular Edema Secondary to Retinal Vein Occlusion: How does ocular imaging guide treatment? Retinal Physician 2011 Apr:29-33.

10. Kiernan DF. Perspective on: Extended dosing regimen for AMD treatment may spur increased use of OCT Ocular Surgery News U.S. Edition, July 25, 2011.

11. Kiernan DF, Donnenfeld ED, Sturm RT, Stoller GS, Carnevale KB, Burke T, Pannullo T. Adding Retina to a Comprehensive Ophthalmology Practice. Ophthalmology Management. 2011 Nov:15(11) 42-46..

12. Kiernan DF. Helzner J. Out of Training – Into the Job Market. Ophthalmology Management. 2012 Jan 16(1);44-45.

13. Kiernan DF. Stopping Dry-to-Wet AMD Conversion. Ophthalmology Management. 2012 Nov 16(11);59-64.

14. Chin EK, Kiernan DF. A 5-step approach to diagnosing uveitis. Ophthalmology Management. 2013 Jun 17(6);34-8.

15. Kiernan DF. Identifying and Managing an Overwhelming Inflammatory Component- Case #4: Bilateral severe peripheral ischemia with extensive leakage owing to diabetic macular edema and neovascularization. Retinal Physician: Case Studies in DME. 2015 Nov/Dec 12: 13-14.

16. Kiernan DF. Treating DME Economically While Reducing Burden. DME: Beyond the Clinical Trials. Retina Today. 2016 Jan/Feb:81-8.

17. Kiernan DF, DeCanio S, Burke T. The Benefits of Longer Lasting Agents for Patients with DME; in: Three Pillars of Success in Patient and Practice Management Strategies in Diabetic Macular Edema. Retina Today 2016 Jul/Aug (2):5-7.

18. Kiernan DF. The Role of Inflammation in Diabetic Eye Disease. Topics in Ocular Antiinflammatories 2018 (23):1-4.

19. Rana HS, Kiernan DF. Non-CNV Predictors of Success of Anti-VEGF for AMD. Retinal Physician Apr 2020 (17):24-29.

Textbook Chapters:

1. Wirostko WJ, Jager RD, Singh R, Kiernan DF, Mieler WF. (2009) Intraocular Foreign Bodies. In: Modern Management of Ocular Trauma. Samuel Boyd, Paul Sternberg Jr., Franco M. Recchia (Eds.) Jaypee Highlights Medical Publishers; pp. 87-108. Daniel F. Kiernan - Curriculum Vitae, page 12

2. Chau FY, Kiernan DF, Lim JI. (2010) Steroids in ARMD and Diabetic Macular Edema. In: Therapy of Ocular Angiogenesis: Principles and Practice. Arup Das and Thomas Friberg (eds.) Lippincott Williams & Wilkins; 2(7):191-208.

3. Shukla SY, Kiernan DF, Lim JI. (2011) Role of Anti-VEGF in Neovascular AMD: What the Clinical Trials Tell Us. In: Macular Degeneration: Causes, Diagnosis and Treatment. Robert B. Catlin and Frank Columbus (eds.) Nova Science Publishers; pp. 29-48.

4. Kang-Mieler JJ, Kiernan DF, Mieler WF. (2012) Drug Delivery to the Posterior Segment. In: Duane’s Ophthalmology 2012 edition. William Tasman and Edward A. Jaeger (Eds.) Wolters Kluwer Health/ Lippincott Williams & Wilkins; 45:18023-42.

5. Kiernan DF. (2012) 18 mini-chapters in the Retina Section of: Encyclopedia of Ophthalmology. Ursula M. Schmidt-Erfurth, George A. Williams and William F. Mieler (Eds.) Springer; in press.

Meeting Lecture Presentations:

1. Kiernan DF, Hariprasad SM, Praley A, Mazzulla DA, Mieler WF. Intravitreally Injected Anti-VEGF Drugs Exert an Effect on Visual Acuity in the Fellow Eye. Presented at the Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 10, 2007. Invest Ophthalmol Vis Sci. 48: 4938. Recipient of National Eye Institute ARVO Retina Subsection Travel Grant Award.

2. Chin EK, Kiernan DF, Hariprasad SM, Singh R, Mieler WF. Superior Surgical Outcomes of 25- over 20-Gauge Transconjunctival Vitrectomy Combined With Cataract Surgery for Vitreoretinal Diseases. Presented at the 3rd Annual Rosalind Franklin School of Health Sciences All School Research Consortium, North Chicago, IL, March 19, 2008. Recipient of First Place Medical Student Presentation Award.

3. Williams Jr BK, Kiernan DF, Jager RD, Lin R, Mieler WF. The Effect of Internal Limiting Membrane Peel During Epiretinal Membrane Removal on Visual Acuity and Recurrence Rate in Diabetic and Non-Diabetic Eyes. Presented at the Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, April 28, 2008. Invest Ophthalmol Vis Sci. 49: 2054.

4. Kiernan DF, Hariprasad SM, Rago JA, Singh R, Chin E, Mieler WF. Prospective Comparison of High-Definition-CirrusTM Optical Coherence Tomography versus Standard-Resolution StratusTM OCT for Quantifying Central Macular Thickness. Presented at the Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, April 28, 2008. Invest Ophthalmol Vis Sci. 49: 1174.

5. Mieler WF, Kiernan DF. Prospective Comparison of CirrusTM Spectral Domain OCT versus StratusTM Time Domain OCT for Quantifying Macular Thickness. Presented at the American Society of Retina Specialists Meeting, Maui, HI, October 14, 2008.

6. Kiernan DF, Hariprasad SM, Mieler WF, Jager RD. The Association of Daily Anticoagulant Use and Intraocular Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration. Presented at the Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 5, 2009. Invest Ophthalmol Vis Sci. 50: 3499.

7. Mieler WF, Kiernan DF. En Face Visualization and Quantification of Photoreceptor Inner/ Outer Segment Junction Using Cirrus Spectral Domain Optical Coherence Tomography and Association with Visual Acuity. Presented at the 33rd annual Macula Society meeting, Tucson, AZ, Feb 27, 2010. Daniel F. Kiernan - Curriculum Vitae, page 13

8. Kiernan DF, Zelkha RU, Lim JI, Hariprasad SM, Mieler WF. En Face Visualization and Quantification of Photoreceptor Inner/ Outer Segment Junction Using Cirrus Spectral Domain Optical Coherence Tomography and Association with Visual Acuity. Presented at the Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 5, 2010. Invest Ophthalmol Vis Sci. 51: 3864.

9. Shah RJ, Kiernan DF, Mieler WF, Grassi MA, Small KW, Kiernan JP, Hariprasad SM. Thirty Year Follow-up of an African-American Family with North Carolina Macular Dystrophy. Presented at the Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 5, 2010. Invest Ophthalmol Vis Sci. 51: 4326. Recipient of American Retina Foundation Travel Grant Award.

10. Kiernan DF, Zelkha R, Hariprasad SM, Lim JI, Mieler WF. En Face Spectral Domain Optical Coherence Tomography Outer Retinal Analysis and Relation to Visual Acuity. Presented at the American Ophthalmological Society Meeting, White Sulphur Springs, WV, May 22, 2010. Recipient of American Retina Foundation Travel Grant Award.

11. Kiernan DF, Zelkha R, Hariprasad SM, Lim JI, Blair MP, Mieler WF. En Face Spectral Domain Optical Coherence Tomography Outer Retinal Analysis and Relation to Visual Acuity. Presented at the American Society of Retinal Specialists Meeting, Vancouver, British Columbia, Canada, August 30, 2010. Recipient of Jedd Retina Research Travel Grant Award.

12. Kiernan DF, Zelkha R, Hariprasad SM, Lim JI, Blair MP, Mieler WF. En Face Spectral Domain Optical Coherence Tomography Outer Retinal Analysis and Relation to Visual Acuity. Presented at the Retina Society Meeting, San Francisco, CA, September 25, 2010. Recipient of 9th Raymond R. Margherio Award.

13. Kiernan DF, Chow CC, Singh R, Ulanksi LJ, Lim JI, Blair NP, Mieler WF. Subsequent Intravitreal Triamcinolone is an Effective Treatment for I-125 Plaque-Associated Retinopathy Recalcitrant to Intravitreal Bevacizumab. Presented at the Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 2, 2011. Invest Ophthalmol Vis Sci. 52: 2105.

14. Chow CC, Blair MP, Kiernan DF, Shapiro MJ. Peripheral Nonperfusion and Tractional Retinal Detachment Associated With Congenital Optic Nerve Anomalies. Presented at the American Academy of Ophthalmology Meeting, Orlando, FL. Paper 075, 2011. Recipient of Best Paper Award.

15. Kiernan DF. Year 3 Visual Acuity Response in Early Nonresponders to 0.2 μg/day Fluocinolone Acetonide Implants: The FAME Study. Presented at the American Academy of Ophthalmology Meeting, New Orleans, LA, 2017.

16. Kiernan DF. Evaluating the Economic and Societal Challenges of Diabetic Retinopathy and Diabetic Macular Edema. Pharmacy Times Continuing Education Specialty Pharmacy Summit, May 2019.

17. Kiernan DF, PALADIN Investigators. Interim 12-Month Anatomical, Safety and Visual Acuity Results From Paladin in Diabetic Macular Edema Patients Receiving 0.19mg Fluocinolone Acetonide (FAc, ILUVIEN) – Analysis of the Prior Dexamethasone Cohort. Presented at the American Society of Retinal Specialists Meeting, Chicago, IL, July 2019.

18. Kiernan DF. Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery. Presented at the American Society of Retinal Specialists Meeting, Seattle, WA (virtual), July 25, 2020. Daniel F. Kiernan - Curriculum Vitae, page 14

19. Hariprasad SM, Singer MA, Kiernan DF, Kavoussi S, Nezgoda J. Early Administration of the Dexamethasone Implant After Anti-VEGF Therapy for the Treatment of Diabetic Macular Edema. Presented at the Retina Society Meeting, New York, NY (virtual), Aug 25, 2020.

20. Kiernan DF, Kiernan CL. Imaging of Posterior Segment: Atrophy and Edema. Presented at the Ophthalmic Photographers’ Society 52nd Annual Program, in association with the American Academy of Ophthalmology Day, Las Vegas, NV (virtual), Nov 13, 2020.

Other Abstracts / Posters:

1. Kiernan DF, Kiernan JP. Piggyback Intraocular Lens Used to Achieve Emmetropia After Unresolved Choroidal Effusion. Presented at the American Society of Cataract and Refractive Surgeons Meeting. Philadelphia, PA. June 4, 2002.

2. Goins KM, Kiernan DF, Farrokh-Siar L. Posterior Capsular Opacification (PCO) After Phacoemulsification in Rabbits Using Rigid and Flexible Haptic Acrylic Lenses and Intracameral Minoxidil. Invest Ophthalmol Vis Sci. 44: 281, 2003

3. Kiernan DF, Kiernan JP. Cosmetic Repair of Scleral Pigment. Presented at the American Society of Cataract and Refractive Surgeons Meeting, San Diego, CA. May 3, 2004.

4. Chang JC, Kiernan DF, Hariprasad SM, Belsare G, Gabrielian A, Patel S, Mieler WF. Acquisition Time and Learning Curve Analysis of High-Definition Cirrus Optical Coherence Tomography Compared to Standard-Resolution Stratus OCT Among Ophthalmology Residents. Invest Ophthalmol Vis Sci. 49: 937, 2008.

5. Singh R, Singh AP, Flaum A, Grant-Acquah K, Kiernan DF, James N, Mieler WF, Jager RD. Comparative Transatlantic Survey of Patient Knowledge and Awareness of and Its Effects on Eye Disease. Invest Ophthalmol Vis Sci. 49: 2132, 2008.

6. Grant-Acquah K, Kiernan DF, Jager RD, Mieler WF. Intraoperative Use of Kenalog for Epiretinal Membrane Removal is Associated with Improved Visual Outcomes and Decreased Membrane Recurrence. Invest Ophthalmol Vis Sci. 49: 2131, 2008.

7. Gabrielian A, Kiernan DF, Hariprasad SM, Lin T, Mieler WF. Effect of Intravitreal Bevacizumab for Retinal Disease on Injected and Fellow Eyes. Invest Ophthalmol Vis Sci. 49: 4570, 2008.

8. Chin EK, Kiernan DF, Hariprasad SM, Singh R, Mieler WF. Superior Surgical Outcomes of 25- over 20-Gauge Transconjunctival Vitrectomy Combined With Cataract Surgery for Vitreoretinal Diseases. Invest Ophthalmol Vis Sci. 49: 4699, 2008.

9. Kiernan DF, Hariprasad SM, Kiernan CL, Chin E, Mieler WF. Prospective Comparison of Cirrus Spectral Domain OCT vs. Stratus Time Domain OCT for Quantifying Macular Thickness. Presented at the American Academy of Ophthalmology Meeting, Atlanta, GA. Abstract 546, 2008.

10. Kiernan DF, Umunna CE, Kiernan CL, Mieler WF, Jager RD. Association of Aspirin, Clopidogrel and Warfarin with Subretinal and Vitreous Hemorrhage in Patients with Exudative Age-Related Macular Degeneration. Presented at the American Academy of Ophthalmology Meeting, Atlanta, GA. Abstract 561, 2008. Daniel F. Kiernan - Curriculum Vitae, page 15

11. Williams Jr BK, Kiernan DF, Jager RD, Lin R, Mieler WF. The Effect of Internal Limiting Membrane Peel During Epiretinal Membrane Removal on Recurrence Rate. Presented at the American Academy of Ophthalmology Meeting, Atlanta, GA. Abstract 275, 2008.

12. Grutsch RM, Kiernan DF, Jager RD, Saidel MA. Demographic and Clinical Features of Anterior Uveitis in Female Patients at a University Ophthalmology Center in Chicago. Invest Ophthalmol Vis Sci. 50: 5060, 2009.

13. Afshar AR, Kiernan DF, Hariprasad SM. Surgical Repair of Chronic Macular Holes. Invest Ophthalmol Vis Sci. 50: 6073, 2009.

14. Kiernan DF, Hariprasad SM, Mieler WF, Jager RD. The Association of Antiplatelets and Anticoagulants with Intraocular Hemorrhage in Patients with Exudative Age-Related Macular Degeneration. Presented at the American Society of Retina Specialists Combined Meeting, New York, NY. Abstract 4547, 2009

15. Kiernan DF, Hariprasad SM, Mieler WF, Jager RD. The Association of Antiplatelets and Anticoagulants with Intraocular Hemorrhage in Patients with Exudative Age-Related Macular Degeneration. Presented at the University of Illinois at Chicago College of Medicine Research Forum, Chicago, IL, Abstract 126, 2009.

16. Kiernan DF, Shah RJ, Hariprasad SM, Grassi MA, Small KW, Kiernan JP, Mieler WF. Thirty-Year Follow-up of an African-American Family with North Carolina Macular Dystrophy. Presented at the American Society of Retinal Specialists Meeting, Vancouver, British Columbia, Canada. Abstract 302, 2010.

17. Shah RJ, Kiernan DF, Hariprasad SM, Grassi MA, Small KW, Kiernan JP, Mieler WF. Thirty Year Follow-up of an African-American Family with North Carolina Macular Dystrophy. Presented at the American Academy of Ophthalmology Meeting, Chicago, IL. Abstract 233, 2010. Recipient of AAO Annual Meeting Program Selection Committee Star Award.

18. Karth PA, Chow CC, Shapiro MA, Blair MP, Kiernan DF. Diode Laser Treatment of Coats Disease in Children. Invest Ophthalmol Vis Sci. 52: 6156, 2011.

19. Rathod RR, Kiernan DF, Lim JI. The Utility of Relaxing Retinectomies in Repair of Recurrent Retinal Detachments with Severe Proliferative Vitreoretinopathy. Presented at the American Society of Retinal Specialists Meeting, Boston, MA. Abstract 330, 2011.

20. Kiernan DF, Chow CC, Singh R, Ulanksi LJ, Lim JI, Blair NP, Mieler WF. Subsequent Intravitreal Triamcinolone is an Effective Treatment for I-125 Plaque-Associated Retinopathy Recalcitrant to Intravitreal Bevacizumab. Presented at the Retina Society Meeting, Rome, Italy, 2011.

21. Kiernan DF, Stoller GL, Carnevale KB, Mondoc NC, Donnenfeld ED. A Single 700 μg Dexamethasone Intravitreal Implant (Ozurdex) Effectively Treats Complex Post-Operative Cystoid Macular Edema. Presented at the Association for Research in Vision and Ophthalmology. Seattle, WA. Abstract 3274-A0125, 2013.

22. Bui KM, Dikopf MS, Hallak J, Kiernan DF, Chow CC, Mieler WF. Treatment of Radiation Maculopathy with Bevacizumab versus Alternating Bevacizumab and Intravitreal Triamcinolone. Presented at the Association for Research in Vision and Ophthalmology. Seattle, WA. Abstract 3841-B0235, 2013. Daniel F. Kiernan - Curriculum Vitae, page 16

23. Kiernan DF, Roth DB. Year 3 Visual Acuity Response in Early Nonresponders to 0.2 ug/day Iluvien fluocinolone acetonide implants: FAME Study post hoc analysis. Presented at the Retina Society Meeting, Boston, MA, 2017.

24. Kiernan DF. The Price of Persistent Edema: Real World Outcomes with the fluocinolone acetonide (FAc) 0.2 μg/day (ILUVIEN®) implant for Diabetic Macular Edema. Presented at the Retina Society Meeting, San Francisco, CA, 2018.

25. Kiernan DF. Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery. Presented at the Association for Research in Vision and Ophthalmology. Baltimore, MD (virtual). Abstract 4375 - A0406, 2020.

26. Semba C, Patel SS, Kunimoto DK, et al. A Novel Intravitreal (IVT) Depot Formulation of Sunitinib (GB-102): 8-Month Results of a Phase 1/2a First-in-Human Single Injection Study in Patients with Neovascular Age-related Macular Degeneration (nAMD) (ADAGIO Study). Presented at the Association for Research in Vision and Ophthalmology. Baltimore, MD (virtual). Abstract 4918 - B0123, 2020.

Videos:

1. Kiernan DF, Hariprasad SM. Alcon 25g Microincisional Vitrectomy Surgery: Vitreous Removal Using Triesence Visualization. http://eyetube.net/v.asp?rekago; EyeTube.net, 2008. Presented at the Advanced Vitreoretinal Techniques and Technology Conference, Chicago, IL. August 23, 2008.

2. Kiernan DF, Hariprasad SM. Alcon 25g Microincisional Vitrectomy Surgery: Elevation of Cortical Vitreous and Hyaloid Using Triesence. http://eyetube.net/v.asp?nejosi; EyeTube.net, 2008. Presented at the Advanced Vitreoretinal Techniques and Technology Conference, Chicago, IL. August 23, 2008.

3. Hariprasad SM, Kiernan DF. Alcon 25g Microincisional Vitrectomy Surgery: Epiretinal Removal with Triesence Enhancement. http://eyetube.net/v.asp?feedel; EyeTube.net, 2008. Presented at the Advanced Vitreoretinal Techniques and Technology Conference, Chicago, IL. August 23, 2008.

OTHER INTERESTS

Family Affairs Oldest of 12 siblings in an adopting, transracial family (youngest adopted from Ethiopia and Liberia) Digital photography Collection of over 5,000 personally-acquired ophthalmic images used in presentations, publications and teaching reviews. Guided The University of Chicago Ophthalmology and Visual Sciences’ purchase of a digital camera for the on-call bag and resident office. Bowling Active Bowler since 1994 11th Annual Retina Fellows Forum Bowling Tournament Top Team Score, 2011 Volleyball Active beach and indoor league player 2005-2016 2nd place, 2007 Players Sports Group Beach Volleyball League Softball Recreational summer leagues, 2006-2013